Olorofim Aspergillus Infection Study

NCT05101187 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Invasive Aspergillosis

Interventions

DRUG: Olorofim
DRUG: AmBisome®

Sponsor

F2G Biotech GmbH

Collaborators

[object Object]
[object Object]